IGF-1 LR3

Concentration: 0.1 mg or 1 mg per vial

Physical Form: White lyophilized powder

Vial Type: Sterile 3 mL glass vial with butyl rubber stopper

Sterility: Depyrogenated, ETO-sterilized, tamper-evident flip-top seal

Presentation: Freeze-dried for improved stability

Engineered analog: Long Arg3 IGF-1 (LR3) is an 83-amino-acid peptide with an N-terminal extension and arginine substitution at position 3, reducing binding to IGF-binding proteins (IGFBPs).

Receptor activity: Potent agonist at the IGF-1 receptor (IGF-1R), activating PI3K/Akt/mTOR signaling to support muscle protein synthesis and satellite cell activation.

Extended half-life: Reduced IGFBP affinity allows longer circulation time and greater tissue availability compared to native IGF-1.

Research applications: Studied in models of muscle hypertrophy, repair, recovery from atrophy, and synergistic interaction with growth hormone.

Metabolic effects: Can lower circulating glucose; hypoglycemia is monitored in controlled experimental settings.

Registry: CAS 946870-92-4 · Molecular weight ≈ 9.1 kDa

Reconstitute with Bacteriostatic Water, Sterile Water for Injection, or 0.6% acetic acid per laboratory protocol.

Mix gently — do not shake vigorously.

If needed, filter-sterilize (0.22 µm).

Use aseptic technique and record diluent, lot, and date for traceability.

Lyophilized (unreconstituted): Store at –20 °C for long term; 2–8 °C for short term. Protect from light and moisture.

After reconstitution: Store at 2–8 °C. For longer retention, aliquot and freeze at –20 °C. Avoid repeated freeze–thaw cycles.

Ensure vials remain sealed with tamper-evident cap until first use.

For research use only (RUO). Not for human consumption, diagnostic, or therapeutic use. By purchasing this product, the user acknowledges responsibility for safe laboratory handling in accordance with institutional and regulatory guidelines.